Inflammatory disorders and atherosclerosis: new therapeutic approaches.
Recent evidence suggests that patients with chronic inflammatory disorders are at increased cardiovascular risk. A number of different mechanisms have been postulated to contribute to atherosclerotic disease progression in these patients including traditional cardiovascular risk factors, cytokine upregulation, immume mediated pathways and increased oxidative stress. Novel treatments target inflammatory pathways and have beneficial effect on rheumatic disease activity however; their impact on cardiovascular risk reduction remains unclear. Further longitudinal studies are required to assess the value of different therapeutic approaches on cardiovascular outcome of these patients.
Vascular Physiology Unit, Institute of Child Health, Great Ormond Street Hospital, London, WC1EH, UK. charakidadoc@gmail.com
Marietta
M
Charakida
Frank
F
O'Neil
Stefano
S
Masi
Nikolaos
N
Papageorgiou
Dimitris
D
Tousoulis
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics / Q000378:metabolism; D002908:Chronic Disease; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D012307:Risk Factors
D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors